Matches in SemOpenAlex for { <https://semopenalex.org/work/W3127963095> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3127963095 endingPage "480" @default.
- W3127963095 startingPage "475" @default.
- W3127963095 abstract "Background: The SUSTAIN-6 trial showed significantly higher rates of retinopathy complications in the semaglutide group compared to placebo. Observational studies have not consistently corroborated this finding, raising questions about the appropriateness of composite variables and whether the relationship exists across the entire drug class or is limited to individual glucagon-like peptide 1 agonists (GLP-1RAs). The study objective was to evaluate the difference between using individual and composite terms to assess associations between GLP-1RAs and diabetic retinopathy events.Research Design and Methods: Reports from the US Food and Drug Administration Adverse Event Reporting System were utilized to examine relationships between GLP-1RAs and diabetic retinopathy events. A disproportionality analysis was conducted using the proportional reporting ratio.Results: Four GLP-1RAs demonstrated signals for diabetic retinopathy events. The GLP-1RA drug class had four diabetic retinopathy signals. Only semaglutide had a signal for the composite diabetic retinopathy outcome. The GLP-1RA drug class and the composite diabetic retinopathy outcome did not meet the PRR signal thresholds.Conclusions: The use of drug class level and composite outcome variables may mask diabetic retinopathy signals in comparison to individual drug assessments. Our results support the SUSTAIN-6 trial findings and suggest an association between four GLP-1RAs and diabetic retinopathy events." @default.
- W3127963095 created "2021-02-15" @default.
- W3127963095 creator A5043419293 @default.
- W3127963095 creator A5089453686 @default.
- W3127963095 date "2021-03-26" @default.
- W3127963095 modified "2023-09-30" @default.
- W3127963095 title "Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy" @default.
- W3127963095 cites W1988100739 @default.
- W3127963095 cites W2035882325 @default.
- W3127963095 cites W2046584449 @default.
- W3127963095 cites W2064630920 @default.
- W3127963095 cites W2119156782 @default.
- W3127963095 cites W2425644022 @default.
- W3127963095 cites W2519510391 @default.
- W3127963095 cites W2625451147 @default.
- W3127963095 cites W2738648627 @default.
- W3127963095 cites W2749709425 @default.
- W3127963095 cites W2785139619 @default.
- W3127963095 cites W2787584324 @default.
- W3127963095 cites W2883137353 @default.
- W3127963095 cites W2891332575 @default.
- W3127963095 cites W2904007338 @default.
- W3127963095 cites W2938328666 @default.
- W3127963095 cites W2948612418 @default.
- W3127963095 cites W2979995164 @default.
- W3127963095 cites W3027159009 @default.
- W3127963095 cites W4246718859 @default.
- W3127963095 doi "https://doi.org/10.1080/14740338.2021.1887136" @default.
- W3127963095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33554677" @default.
- W3127963095 hasPublicationYear "2021" @default.
- W3127963095 type Work @default.
- W3127963095 sameAs 3127963095 @default.
- W3127963095 citedByCount "5" @default.
- W3127963095 countsByYear W31279630952021 @default.
- W3127963095 countsByYear W31279630952022 @default.
- W3127963095 countsByYear W31279630952023 @default.
- W3127963095 crossrefType "journal-article" @default.
- W3127963095 hasAuthorship W3127963095A5043419293 @default.
- W3127963095 hasAuthorship W3127963095A5089453686 @default.
- W3127963095 hasConcept C126322002 @default.
- W3127963095 hasConcept C134018914 @default.
- W3127963095 hasConcept C197934379 @default.
- W3127963095 hasConcept C23131810 @default.
- W3127963095 hasConcept C2777180221 @default.
- W3127963095 hasConcept C2778176773 @default.
- W3127963095 hasConcept C2778313320 @default.
- W3127963095 hasConcept C2779829184 @default.
- W3127963095 hasConcept C2780035454 @default.
- W3127963095 hasConcept C2781308992 @default.
- W3127963095 hasConcept C2909862629 @default.
- W3127963095 hasConcept C555293320 @default.
- W3127963095 hasConcept C71924100 @default.
- W3127963095 hasConcept C98274493 @default.
- W3127963095 hasConceptScore W3127963095C126322002 @default.
- W3127963095 hasConceptScore W3127963095C134018914 @default.
- W3127963095 hasConceptScore W3127963095C197934379 @default.
- W3127963095 hasConceptScore W3127963095C23131810 @default.
- W3127963095 hasConceptScore W3127963095C2777180221 @default.
- W3127963095 hasConceptScore W3127963095C2778176773 @default.
- W3127963095 hasConceptScore W3127963095C2778313320 @default.
- W3127963095 hasConceptScore W3127963095C2779829184 @default.
- W3127963095 hasConceptScore W3127963095C2780035454 @default.
- W3127963095 hasConceptScore W3127963095C2781308992 @default.
- W3127963095 hasConceptScore W3127963095C2909862629 @default.
- W3127963095 hasConceptScore W3127963095C555293320 @default.
- W3127963095 hasConceptScore W3127963095C71924100 @default.
- W3127963095 hasConceptScore W3127963095C98274493 @default.
- W3127963095 hasIssue "4" @default.
- W3127963095 hasLocation W31279630951 @default.
- W3127963095 hasOpenAccess W3127963095 @default.
- W3127963095 hasPrimaryLocation W31279630951 @default.
- W3127963095 hasRelatedWork W2150699126 @default.
- W3127963095 hasRelatedWork W2401570230 @default.
- W3127963095 hasRelatedWork W3127963095 @default.
- W3127963095 hasRelatedWork W3161069591 @default.
- W3127963095 hasRelatedWork W3190746054 @default.
- W3127963095 hasRelatedWork W4297687594 @default.
- W3127963095 hasRelatedWork W4323344191 @default.
- W3127963095 hasRelatedWork W2253550537 @default.
- W3127963095 hasRelatedWork W2612723704 @default.
- W3127963095 hasRelatedWork W943310924 @default.
- W3127963095 hasVolume "20" @default.
- W3127963095 isParatext "false" @default.
- W3127963095 isRetracted "false" @default.
- W3127963095 magId "3127963095" @default.
- W3127963095 workType "article" @default.